Patient & Visitor InformationContact Us
  • Genitourinary Protocols

  • Renal

    1. LS-P-GSK Renal: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
      PI: Anthony Mega, MD
      Sites: The Miriam Hospital

    2. BrUOG 275: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer, and Renal Cancer: A Phase II Brown University Oncology Study
      PI: Maria Constantinou, MD
      Site: The Miriam Hospital, Rhode Island Hospital

    3. LS-P-SGN75-002: A phase 1b, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma
      PI: Anthony Mega, MD
      Site: The Miriam Hospital

    Prostate

    1. BrUOG 255: A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer
      PI: Anthony Mega, MD
      Site: The Miriam Hospital

    2. BrUOG 246: Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients with PSA Elevation (>0.1 - < 2.0 ng/mL) Following Radical Prostatectomy
      PI: Howard Safran, MD
      Site: The Miriam Hospital

    3. BrUOG 275: Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer, and Renal Cancer: A Phase II Brown University Oncology Study
      PI: Maria Constantinou, MD
      Site: The Miriam Hospital, Rhode Island Hospital

    4. LS-P-PSMA ADC 2301: A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Castration-Resistant Metastatic Prostate Cancer (CRMPC)
      PI: Anthony Mega, MD
      Site: The Miriam Hospital